

Global Poxviridae Infections Drug Market Research Report 2025(Status and Outlook)

<https://marketpublishers.com/r/GA3C39E3F46DEN.html>

Date: October 2025

Pages: 146

Price: US\$ 3,200.00 (Single User License)

ID: GA3C39E3F46DEN

Abstracts

The market for Poxviridae infections drugs encompasses pharmaceutical products and therapeutics designed to prevent and treat infections caused by viruses within the Poxviridae family, including variola virus (smallpox), vaccinia virus, monkeypox virus, molluscum contagiosum virus, and other related zoonotic and human pathogens; these interventions range from traditional live-virus vaccines (e.g., ACAM2000) to newer antiviral agents (e.g., tecovirimat), immunoglobulins, and investigational drugs targeting viral replication or host immune responses, with applications spanning public health preparedness, outbreak response, routine clinical management, and biodefense initiatives. Market dynamics are influenced by factors such as government stockpiling policies, emerging zoonotic transmission events (e.g., mpox outbreaks), advancements in drug development targeting poxvirus-specific enzymes (e.g., VP37), and ongoing research into broad-spectrum antivirals, with regulatory pathways often expedited under emergency use authorities or orphan drug designations due to the high-consequence nature of some poxviral diseases.

The global Poxviridae Infections Drug market size was estimated at USD 1250.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 5.50% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Poxviridae Infections Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the

industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Poxviridae Infections Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Poxviridae Infections Drug market.

Global Poxviridae Infections Drug Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Bavarian Nordic A/S
BioFactorInc.
CEL-SCI Corporation
ChimerixInc.
China Biologic ProductsInc.
CJ HealthCare Corp.
EpiVaxInc.
N & N Pharmaceuticals Inc.

SIGA Technologies Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.

Market Segmentation (by Type)

CJ-40011
24a
BA-368
Others

Market Segmentation (by Application)

Hospital
Clinic
Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Poxviridae Infections Drug Market
Overview of the regional outlook of the Poxviridae Infections Drug Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Poxviridae Infections Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Poxviridae Infections Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth

as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Poxviridae Infections Drug

1.2 Key Market Segments

1.2.1 Poxviridae Infections Drug Segment by Type

1.2.2 Poxviridae Infections Drug Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 POXVIRIDAE INFECTIONS DRUG MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Poxviridae Infections Drug Market Size (M USD) Estimates and Forecasts (2020-2033)

2.1.2 Global Poxviridae Infections Drug Sales Estimates and Forecasts (2020-2033)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 POXVIRIDAE INFECTIONS DRUG MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant

3.2 Global Poxviridae Infections Drug Product Life Cycle

3.3 Global Poxviridae Infections Drug Sales by Manufacturers (2020-2025)

3.4 Global Poxviridae Infections Drug Revenue Market Share by Manufacturers (2020-2025)

3.5 Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Poxviridae Infections Drug Average Price by Manufacturers (2020-2025)

3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types

3.8 Poxviridae Infections Drug Market Competitive Situation and Trends

3.8.1 Poxviridae Infections Drug Market Concentration Rate

3.8.2 Global 5 and 10 Largest Poxviridae Infections Drug Players Market Share by Revenue

3.8.3 Mergers & Acquisitions, Expansion

4 POXVIRIDAE INFECTIONS DRUG INDUSTRY CHAIN ANALYSIS

4.1 Poxviridae Infections Drug Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF POXVIRIDAE INFECTIONS DRUG MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Industry News

5.4.1 New Product Developments

5.4.2 Mergers & Acquisitions

5.4.3 Expansions

5.4.4 Collaboration/Supply Contracts

5.5 PEST Analysis

5.5.1 Industry Policies Analysis

5.5.2 Economic Environment Analysis

5.5.3 Social Environment Analysis

5.5.4 Technological Environment Analysis

5.6 Global Poxviridae Infections Drug Market Porter's Five Forces Analysis

5.6.1 Global Trade Frictions

5.6.2 U.S. Tariff Policy ? April 2025

5.6.3 Global Trade Frictions and Their Impacts to Poxviridae Infections Drug Market

5.7 ESG Ratings of Leading Companies

6 POXVIRIDAE INFECTIONS DRUG MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Poxviridae Infections Drug Sales Market Share by Type (2020-2025)

6.3 Global Poxviridae Infections Drug Market Size Market Share by Type (2020-2025)

6.4 Global Poxviridae Infections Drug Price by Type (2020-2025)

7 POXVIRIDAE INFECTIONS DRUG MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Poxviridae Infections Drug Market Sales by Application (2020-2025)
- 7.3 Global Poxviridae Infections Drug Market Size (M USD) by Application (2020-2025)
- 7.4 Global Poxviridae Infections Drug Sales Growth Rate by Application (2020-2025)

8 POXVIRIDAE INFECTIONS DRUG MARKET SALES BY REGION

- 8.1 Global Poxviridae Infections Drug Sales by Region
 - 8.1.1 Global Poxviridae Infections Drug Sales by Region
 - 8.1.2 Global Poxviridae Infections Drug Sales Market Share by Region
- 8.2 Global Poxviridae Infections Drug Market Size by Region
 - 8.2.1 Global Poxviridae Infections Drug Market Size by Region
 - 8.2.2 Global Poxviridae Infections Drug Market Size Market Share by Region
- 8.3 North America
 - 8.3.1 North America Poxviridae Infections Drug Sales by Country
 - 8.3.2 North America Poxviridae Infections Drug Market Size by Country
 - 8.3.3 U.S. Market Overview
 - 8.3.4 Canada Market Overview
 - 8.3.5 Mexico Market Overview
- 8.4 Europe
 - 8.4.1 Europe Poxviridae Infections Drug Sales by Country
 - 8.4.2 Europe Poxviridae Infections Drug Market Size by Country
 - 8.4.3 Germany Market Overview
 - 8.4.4 France Market Overview
 - 8.4.5 U.K. Market Overview
 - 8.4.6 Italy Market Overview
 - 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
 - 8.5.1 Asia Pacific Poxviridae Infections Drug Sales by Region
 - 8.5.2 Asia Pacific Poxviridae Infections Drug Market Size by Region
 - 8.5.3 China Market Overview
 - 8.5.4 Japan Market Overview
 - 8.5.5 South Korea Market Overview
 - 8.5.6 India Market Overview
 - 8.5.7 Southeast Asia Market Overview
- 8.6 South America
 - 8.6.1 South America Poxviridae Infections Drug Sales by Country
 - 8.6.2 South America Poxviridae Infections Drug Market Size by Country

8.6.3 Brazil Market Overview

8.6.4 Argentina Market Overview

8.6.5 Columbia Market Overview

8.7 Middle East and Africa

8.7.1 Middle East and Africa Poxviridae Infections Drug Sales by Region

8.7.2 Middle East and Africa Poxviridae Infections Drug Market Size by Region

8.7.3 Saudi Arabia Market Overview

8.7.4 UAE Market Overview

8.7.5 Egypt Market Overview

8.7.6 Nigeria Market Overview

8.7.7 South Africa Market Overview

9 POXVIRIDAE INFECTIONS DRUG MARKET PRODUCTION BY REGION

9.1 Global Production of Poxviridae Infections Drug by Region(2020-2025)

9.2 Global Poxviridae Infections Drug Revenue Market Share by Region (2020-2025)

9.3 Global Poxviridae Infections Drug Production, Revenue, Price and Gross Margin (2020-2025)

9.4 North America Poxviridae Infections Drug Production

9.4.1 North America Poxviridae Infections Drug Production Growth Rate (2020-2025)

9.4.2 North America Poxviridae Infections Drug Production, Revenue, Price and Gross Margin (2020-2025)

9.5 Europe Poxviridae Infections Drug Production

9.5.1 Europe Poxviridae Infections Drug Production Growth Rate (2020-2025)

9.5.2 Europe Poxviridae Infections Drug Production, Revenue, Price and Gross Margin (2020-2025)

9.6 Japan Poxviridae Infections Drug Production (2020-2025)

9.6.1 Japan Poxviridae Infections Drug Production Growth Rate (2020-2025)

9.6.2 Japan Poxviridae Infections Drug Production, Revenue, Price and Gross Margin (2020-2025)

9.7 China Poxviridae Infections Drug Production (2020-2025)

9.7.1 China Poxviridae Infections Drug Production Growth Rate (2020-2025)

9.7.2 China Poxviridae Infections Drug Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Bavarian Nordic A/S

10.1.1 Bavarian Nordic A/S Basic Information

- 10.1.2 Bavarian Nordic A/S Poxviridae Infections Drug Product Overview
- 10.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Product Market Performance
- 10.1.4 Bavarian Nordic A/S Business Overview
- 10.1.5 Bavarian Nordic A/S SWOT Analysis
- 10.1.6 Bavarian Nordic A/S Recent Developments
- 10.2 BioFactualInc.
 - 10.2.1 BioFactualInc. Basic Information
 - 10.2.2 BioFactualInc. Poxviridae Infections Drug Product Overview
 - 10.2.3 BioFactualInc. Poxviridae Infections Drug Product Market Performance
 - 10.2.4 BioFactualInc. Business Overview
 - 10.2.5 BioFactualInc. SWOT Analysis
 - 10.2.6 BioFactualInc. Recent Developments
- 10.3 CEL-SCI Corporation
 - 10.3.1 CEL-SCI Corporation Basic Information
 - 10.3.2 CEL-SCI Corporation Poxviridae Infections Drug Product Overview
 - 10.3.3 CEL-SCI Corporation Poxviridae Infections Drug Product Market Performance
 - 10.3.4 CEL-SCI Corporation Business Overview
 - 10.3.5 CEL-SCI Corporation SWOT Analysis
 - 10.3.6 CEL-SCI Corporation Recent Developments
- 10.4 ChimerixInc.
 - 10.4.1 ChimerixInc. Basic Information
 - 10.4.2 ChimerixInc. Poxviridae Infections Drug Product Overview
 - 10.4.3 ChimerixInc. Poxviridae Infections Drug Product Market Performance
 - 10.4.4 ChimerixInc. Business Overview
 - 10.4.5 ChimerixInc. Recent Developments
- 10.5 China Biologic ProductsInc.
 - 10.5.1 China Biologic ProductsInc. Basic Information
 - 10.5.2 China Biologic ProductsInc. Poxviridae Infections Drug Product Overview
 - 10.5.3 China Biologic ProductsInc. Poxviridae Infections Drug Product Market Performance
 - 10.5.4 China Biologic ProductsInc. Business Overview
 - 10.5.5 China Biologic ProductsInc. Recent Developments
- 10.6 CJ HealthCare Corp.
 - 10.6.1 CJ HealthCare Corp. Basic Information
 - 10.6.2 CJ HealthCare Corp. Poxviridae Infections Drug Product Overview
 - 10.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Product Market Performance
 - 10.6.4 CJ HealthCare Corp. Business Overview
 - 10.6.5 CJ HealthCare Corp. Recent Developments
- 10.7 EpiVaxInc.

- 10.7.1 EpiVaxInc. Basic Information
- 10.7.2 EpiVaxInc. Poxviridae Infections Drug Product Overview
- 10.7.3 EpiVaxInc. Poxviridae Infections Drug Product Market Performance
- 10.7.4 EpiVaxInc. Business Overview
- 10.7.5 EpiVaxInc. Recent Developments
- 10.8 N and N Pharmaceuticals Inc.
 - 10.8.1 N and N Pharmaceuticals Inc. Basic Information
 - 10.8.2 N and N Pharmaceuticals Inc. Poxviridae Infections Drug Product Overview
 - 10.8.3 N and N Pharmaceuticals Inc. Poxviridae Infections Drug Product Market Performance
 - 10.8.4 N and N Pharmaceuticals Inc. Business Overview
 - 10.8.5 N and N Pharmaceuticals Inc. Recent Developments
- 10.9 SIGA TechnologiesInc.
 - 10.9.1 SIGA TechnologiesInc. Basic Information
 - 10.9.2 SIGA TechnologiesInc. Poxviridae Infections Drug Product Overview
 - 10.9.3 SIGA TechnologiesInc. Poxviridae Infections Drug Product Market Performance
 - 10.9.4 SIGA TechnologiesInc. Business Overview
 - 10.9.5 SIGA TechnologiesInc. Recent Developments
- 10.10 Takeda Pharmaceutical Company Limited
 - 10.10.1 Takeda Pharmaceutical Company Limited Basic Information
 - 10.10.2 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Overview
 - 10.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Market Performance
 - 10.10.4 Takeda Pharmaceutical Company Limited Business Overview
 - 10.10.5 Takeda Pharmaceutical Company Limited Recent Developments
- 10.11 Tonix Pharmaceuticals Holding Corp.
 - 10.11.1 Tonix Pharmaceuticals Holding Corp. Basic Information
 - 10.11.2 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Overview
 - 10.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Market Performance
 - 10.11.4 Tonix Pharmaceuticals Holding Corp. Business Overview
 - 10.11.5 Tonix Pharmaceuticals Holding Corp. Recent Developments
- 10.12 Verrica Pharmaceuticals Inc.
 - 10.12.1 Verrica Pharmaceuticals Inc. Basic Information
 - 10.12.2 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Overview
 - 10.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Market Performance

10.12.4 Verrica Pharmaceuticals Inc. Business Overview

10.12.5 Verrica Pharmaceuticals Inc. Recent Developments

11 POXVIRIDAE INFECTIONS DRUG MARKET FORECAST BY REGION

11.1 Global Poxviridae Infections Drug Market Size Forecast

11.2 Global Poxviridae Infections Drug Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Poxviridae Infections Drug Market Size Forecast by Country

11.2.3 Asia Pacific Poxviridae Infections Drug Market Size Forecast by Region

11.2.4 South America Poxviridae Infections Drug Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Sales of Poxviridae Infections Drug by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)

12.1 Global Poxviridae Infections Drug Market Forecast by Type (2026-2033)

12.1.1 Global Forecasted Sales of Poxviridae Infections Drug by Type (2026-2033)

12.1.2 Global Poxviridae Infections Drug Market Size Forecast by Type (2026-2033)

12.1.3 Global Forecasted Price of Poxviridae Infections Drug by Type (2026-2033)

12.2 Global Poxviridae Infections Drug Market Forecast by Application (2026-2033)

12.2.1 Global Poxviridae Infections Drug Sales (K MT) Forecast by Application

12.2.2 Global Poxviridae Infections Drug Market Size (M USD) Forecast by Application (2026-2033)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Poxviridae Infections Drug Market Size Comparison by Region (M USD)

Table 5. Global Poxviridae Infections Drug Sales (K MT) by Manufacturers (2020-2025)

Table 6. Global Poxviridae Infections Drug Sales Market Share by Manufacturers (2020-2025)

Table 7. Global Poxviridae Infections Drug Revenue (M USD) by Manufacturers (2020-2025)

Table 8. Global Poxviridae Infections Drug Revenue Share by Manufacturers (2020-2025)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Poxviridae Infections Drug as of 2024)

Table 10. Global Market Poxviridae Infections Drug Average Price (USD/KG) of Key Manufacturers (2020-2025)

Table 11. Manufacturers? Manufacturing Sites, Areas Served

Table 12. Manufacturers? Product Type

Table 13. Global Poxviridae Infections Drug Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Market Overview of Key Raw Materials

Table 16. Midstream Market Analysis

Table 17. Downstream Customer Analysis

Table 18. Key Development Trends

Table 19. Driving Factors

Table 20. Poxviridae Infections Drug Market Challenges

Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026

Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027

Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026

Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries

Table 25. Global Poxviridae Infections Drug Sales by Type (K MT)

Table 26. Global Poxviridae Infections Drug Market Size by Type (M USD)

Table 27. Global Poxviridae Infections Drug Sales (K MT) by Type (2020-2025)

Table 28. Global Poxviridae Infections Drug Sales Market Share by Type (2020-2025)

Table 29. Global Poxviridae Infections Drug Market Size (M USD) by Type (2020-2025)
Table 30. Global Poxviridae Infections Drug Market Size Share by Type (2020-2025)
Table 31. Global Poxviridae Infections Drug Price (USD/KG) by Type (2020-2025)
Table 32. Global Poxviridae Infections Drug Sales (K MT) by Application
Table 33. Global Poxviridae Infections Drug Market Size by Application
Table 34. Global Poxviridae Infections Drug Sales by Application (2020-2025) & (K MT)
Table 35. Global Poxviridae Infections Drug Sales Market Share by Application (2020-2025)
Table 36. Global Poxviridae Infections Drug Market Size by Application (2020-2025) & (M USD)
Table 37. Global Poxviridae Infections Drug Market Share by Application (2020-2025)
Table 38. Global Poxviridae Infections Drug Sales Growth Rate by Application (2020-2025)
Table 39. Global Poxviridae Infections Drug Sales by Region (2020-2025) & (K MT)
Table 40. Global Poxviridae Infections Drug Sales Market Share by Region (2020-2025)
Table 41. Global Poxviridae Infections Drug Market Size by Region (2020-2025) & (M USD)
Table 42. Global Poxviridae Infections Drug Market Size Market Share by Region (2020-2025)
Table 43. North America Poxviridae Infections Drug Sales by Country (2020-2025) & (K MT)
Table 44. North America Poxviridae Infections Drug Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Poxviridae Infections Drug Sales by Country (2020-2025) & (K MT)
Table 46. Europe Poxviridae Infections Drug Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Poxviridae Infections Drug Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Poxviridae Infections Drug Market Size by Region (2020-2025) & (M USD)
Table 49. South America Poxviridae Infections Drug Sales by Country (2020-2025) & (K MT)
Table 50. South America Poxviridae Infections Drug Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Poxviridae Infections Drug Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Poxviridae Infections Drug Market Size by Region (2020-2025) & (M USD)
Table 53. Global Poxviridae Infections Drug Production (K MT) by Region(2020-2025)

Table 54. Global Poxviridae Infections Drug Revenue (US\$ Million) by Region (2020-2025)

Table 55. Global Poxviridae Infections Drug Revenue Market Share by Region (2020-2025)

Table 56. Global Poxviridae Infections Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 57. North America Poxviridae Infections Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 58. Europe Poxviridae Infections Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 59. Japan Poxviridae Infections Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 60. China Poxviridae Infections Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 61. Bavarian Nordic A/S Basic Information

Table 62. Bavarian Nordic A/S Poxviridae Infections Drug Product Overview

Table 63. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 64. Bavarian Nordic A/S Business Overview

Table 65. Bavarian Nordic A/S SWOT Analysis

Table 66. Bavarian Nordic A/S Recent Developments

Table 67. BioFacturalInc. Basic Information

Table 68. BioFacturalInc. Poxviridae Infections Drug Product Overview

Table 69. BioFacturalInc. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 70. BioFacturalInc. Business Overview

Table 71. BioFacturalInc. SWOT Analysis

Table 72. BioFacturalInc. Recent Developments

Table 73. CEL-SCI Corporation Basic Information

Table 74. CEL-SCI Corporation Poxviridae Infections Drug Product Overview

Table 75. CEL-SCI Corporation Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 76. CEL-SCI Corporation Business Overview

Table 77. CEL-SCI Corporation SWOT Analysis

Table 78. CEL-SCI Corporation Recent Developments

Table 79. ChimerixInc. Basic Information

Table 80. ChimerixInc. Poxviridae Infections Drug Product Overview

Table 81. ChimerixInc. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 82. ChimerixInc. Business Overview
Table 83. ChimerixInc. Recent Developments
Table 84. China Biologic ProductsInc. Basic Information
Table 85. China Biologic ProductsInc. Poxviridae Infections Drug Product Overview
Table 86. China Biologic ProductsInc. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. China Biologic ProductsInc. Business Overview
Table 88. China Biologic ProductsInc. Recent Developments
Table 89. CJ HealthCare Corp. Basic Information
Table 90. CJ HealthCare Corp. Poxviridae Infections Drug Product Overview
Table 91. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. CJ HealthCare Corp. Business Overview
Table 93. CJ HealthCare Corp. Recent Developments
Table 94. EpiVaxInc. Basic Information
Table 95. EpiVaxInc. Poxviridae Infections Drug Product Overview
Table 96. EpiVaxInc. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. EpiVaxInc. Business Overview
Table 98. EpiVaxInc. Recent Developments
Table 99. N and N Pharmaceuticals Inc. Basic Information
Table 100. N and N Pharmaceuticals Inc. Poxviridae Infections Drug Product Overview
Table 101. N and N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. N and N Pharmaceuticals Inc. Business Overview
Table 103. N and N Pharmaceuticals Inc. Recent Developments
Table 104. SIGA TechnologiesInc. Basic Information
Table 105. SIGA TechnologiesInc. Poxviridae Infections Drug Product Overview
Table 106. SIGA TechnologiesInc. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. SIGA TechnologiesInc. Business Overview
Table 108. SIGA TechnologiesInc. Recent Developments
Table 109. Takeda Pharmaceutical Company Limited Basic Information
Table 110. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Overview
Table 111. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Takeda Pharmaceutical Company Limited Business Overview
Table 113. Takeda Pharmaceutical Company Limited Recent Developments

Table 114. Tonix Pharmaceuticals Holding Corp. Basic Information
Table 115. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Overview
Table 116. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 117. Tonix Pharmaceuticals Holding Corp. Business Overview
Table 118. Tonix Pharmaceuticals Holding Corp. Recent Developments
Table 119. Verrica Pharmaceuticals Inc. Basic Information
Table 120. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Overview
Table 121. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 122. Verrica Pharmaceuticals Inc. Business Overview
Table 123. Verrica Pharmaceuticals Inc. Recent Developments
Table 124. Global Poxviridae Infections Drug Sales Forecast by Region (2026-2033) & (K MT)
Table 125. Global Poxviridae Infections Drug Market Size Forecast by Region (2026-2033) & (M USD)
Table 126. North America Poxviridae Infections Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 127. North America Poxviridae Infections Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 128. Europe Poxviridae Infections Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 129. Europe Poxviridae Infections Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 130. Asia Pacific Poxviridae Infections Drug Sales Forecast by Region (2026-2033) & (K MT)
Table 131. Asia Pacific Poxviridae Infections Drug Market Size Forecast by Region (2026-2033) & (M USD)
Table 132. South America Poxviridae Infections Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 133. South America Poxviridae Infections Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 134. Middle East and Africa Poxviridae Infections Drug Sales Forecast by Country (2026-2033) & (Units)
Table 135. Middle East and Africa Poxviridae Infections Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 136. Global Poxviridae Infections Drug Sales Forecast by Type (2026-2033) & (K MT)

Table 137. Global Poxviridae Infections Drug Market Size Forecast by Type
(2026-2033) & (M USD)

Table 138. Global Poxviridae Infections Drug Price Forecast by Type (2026-2033) &
(USD/KG)

Table 139. Global Poxviridae Infections Drug Sales (K MT) Forecast by Application
(2026-2033)

Table 140. Global Poxviridae Infections Drug Market Size Forecast by Application
(2026-2033) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Poxviridae Infections Drug
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Poxviridae Infections Drug Market Size (M USD), 2024-2033
- Figure 5. Global Poxviridae Infections Drug Market Size (M USD) (2020-2033)
- Figure 6. Global Poxviridae Infections Drug Sales (K MT) & (2020-2033)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Poxviridae Infections Drug Market Size by Country (M USD)
- Figure 11. Company Assessment Quadrant
- Figure 12. Global Poxviridae Infections Drug Product Life Cycle
- Figure 13. Poxviridae Infections Drug Sales Share by Manufacturers in 2024
- Figure 14. Global Poxviridae Infections Drug Revenue Share by Manufacturers in 2024
- Figure 15. Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
- Figure 16. Global Market Poxviridae Infections Drug Average Price (USD/KG) of Key Manufacturers in 2024
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Poxviridae Infections Drug Revenue in 2024
- Figure 18. Industry Chain Map of Poxviridae Infections Drug
- Figure 19. Global Poxviridae Infections Drug Market PEST Analysis
- Figure 20. Global Poxviridae Infections Drug Market Porter's Five Forces Analysis
- Figure 21. Global Merchandise Trade as a Percentage Of GDP
- Figure 22. US - Imports of Goods by Country
- Figure 23. China Exports by Country
- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 26. Global Poxviridae Infections Drug Market Share by Type
- Figure 27. Sales Market Share of Poxviridae Infections Drug by Type (2020-2025)
- Figure 28. Sales Market Share of Poxviridae Infections Drug by Type in 2024
- Figure 29. Market Size Share of Poxviridae Infections Drug by Type (2020-2025)
- Figure 30. Market Size Share of Poxviridae Infections Drug by Type in 2024
- Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 32. Global Poxviridae Infections Drug Market Share by Application

Figure 33. Global Poxviridae Infections Drug Sales Market Share by Application (2020-2025)

Figure 34. Global Poxviridae Infections Drug Sales Market Share by Application in 2024

Figure 35. Global Poxviridae Infections Drug Market Share by Application (2020-2025)

Figure 36. Global Poxviridae Infections Drug Market Share by Application in 2024

Figure 37. Global Poxviridae Infections Drug Sales Growth Rate by Application (2020-2025)

Figure 38. Global Poxviridae Infections Drug Sales Market Share by Region (2020-2025)

Figure 39. Global Poxviridae Infections Drug Market Size Market Share by Region (2020-2025)

Figure 40. North America Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 41. North America Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 42. North America Poxviridae Infections Drug Sales Market Share by Country in 2024

Figure 43. North America Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 44. North America Poxviridae Infections Drug Market Size Market Share by Country in 2024

Figure 45. U.S. Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 46. U.S. Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 47. Canada Poxviridae Infections Drug Sales (K MT) and Growth Rate (2020-2025)

Figure 48. Canada Poxviridae Infections Drug Market Size (M USD) and Growth Rate (2020-2025)

Figure 49. Mexico Poxviridae Infections Drug Sales (Units) and Growth Rate (2020-2025)

Figure 50. Mexico Poxviridae Infections Drug Market Size (Units) and Growth Rate (2020-2025)

Figure 51. Europe Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 52. Europe Poxviridae Infections Drug Sales Market Share by Country in 2024

Figure 53. Europe Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 54. Europe Poxviridae Infections Drug Market Size Market Share by Country in

2024

Figure 55. Germany Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 56. Germany Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. France Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 58. France Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. U.K. Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 60. U.K. Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 61. Italy Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. Italy Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Spain Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 64. Spain Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 65. Asia Pacific Poxviridae Infections Drug Sales and Growth Rate (K MT)

Figure 66. Asia Pacific Poxviridae Infections Drug Sales Market Share by Region in 2024

Figure 67. Asia Pacific Poxviridae Infections Drug Market Size Market Share by Region in 2024

Figure 68. China Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 69. China Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 70. Japan Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 71. Japan Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 72. South Korea Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 73. South Korea Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 74. India Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K

MT)

Figure 75. India Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 76. Southeast Asia Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 77. Southeast Asia Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 78. South America Poxviridae Infections Drug Sales and Growth Rate (K MT)

Figure 79. South America Poxviridae Infections Drug Sales Market Share by Country in 2024

Figure 80. South America Poxviridae Infections Drug Market Size and Growth Rate (M USD)

Figure 81. South America Poxviridae Infections Drug Market Size Market Share by Country in 2024

Figure 82. Brazil Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 83. Brazil Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 84. Argentina Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 85. Argentina Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 86. Columbia Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 87. Columbia Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 88. Middle East and Africa Poxviridae Infections Drug Sales and Growth Rate (K MT)

Figure 89. Middle East and Africa Poxviridae Infections Drug Sales Market Share by Region in 2024

Figure 90. Middle East and Africa Poxviridae Infections Drug Market Size and Growth Rate (M USD)

Figure 91. Middle East and Africa Poxviridae Infections Drug Market Size Market Share by Region in 2024

Figure 92. Saudi Arabia Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 93. Saudi Arabia Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 94. UAE Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K

MT)

Figure 95. UAE Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 96. Egypt Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 97. Egypt Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 98. Nigeria Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 99. Nigeria Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 100. South Africa Poxviridae Infections Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 101. South Africa Poxviridae Infections Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 102. Global Poxviridae Infections Drug Production Market Share by Region (2020-2025)

Figure 103. North America Poxviridae Infections Drug Production (K MT) Growth Rate (2020-2025)

Figure 104. Europe Poxviridae Infections Drug Production (K MT) Growth Rate (2020-2025)

Figure 105. Japan Poxviridae Infections Drug Production (K MT) Growth Rate (2020-2025)

Figure 106. China Poxviridae Infections Drug Production (K MT) Growth Rate (2020-2025)

Figure 107. Global Poxviridae Infections Drug Sales Forecast by Volume (2020-2033) & (K MT)

Figure 108. Global Poxviridae Infections Drug Market Size Forecast by Value (2020-2033) & (M USD)

Figure 109. Global Poxviridae Infections Drug Sales Market Share Forecast by Type (2026-2033)

Figure 110. Global Poxviridae Infections Drug Market Share Forecast by Type (2026-2033)

Figure 111. Global Poxviridae Infections Drug Sales Forecast by Application (2026-2033)

Figure 112. Global Poxviridae Infections Drug Market Share Forecast by Application (2026-2033)

I would like to order

Product name: Global Poxviridae Infections Drug Market Research Report 2025(Status and Outlook)

Product link: <https://marketpublishers.com/r/GA3C39E3F46DEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA3C39E3F46DEN.html>